The application of support vector regression for prediction of the antiallodynic effect of drug combinations in the mouse model of streptozocin-induced diabetic neuropathy

Computer Methods and Programs in Biomedicine

Volumn 111, Issue 2, 2013, Pages 330-337

  Sałat, Robert ^a   Sałat, Kinga ^b  

^a WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Diabetes induced neuropathic pain; Dihydrofuran 2 one; Mechanical allodynia; Pregabalin; Streptozocin; Support vector regression

Indexed keywords

DIHYDROFURAN-2-ONE; MECHANICAL ALLODYNIA; NEUROPATHIC PAIN; PREGABALIN; STREPTOZOCIN; SUPPORT VECTOR REGRESSION (SVR);

DRUG INTERACTIONS; HEALTH; MAMMALS; REGRESSION ANALYSIS;

DRUG DOSAGE;

(3 [4 (3 TRIFLUOROMETHYL PHENYL) PIPERAZIN 1 YL] DIHYDROFURAN 2 ONE DIHYDROCHLORIDE; ANALGESIC AGENT; PREGABALIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; IN VIVO STUDY; MALE; MECHANICAL STIMULATION; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; STREPTOZOCIN DIABETES; SUPPORT VECTOR MACHINE;

DIABETES-INDUCED NEUROPATHIC PAIN; DIHYDROFURAN-2-ONE; MECHANICAL ALLODYNIA; PREGABALIN; STREPTOZOCIN; SUPPORT VECTOR REGRESSION;

4-BUTYROLACTONE; ALGORITHMS; ANALGESICS; ANIMALS; COMPUTER SIMULATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FURANS; GAMMA-AMINOBUTYRIC ACID; HYPERALGESIA; MALE; MICE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PIPERAZINES; SOFTWARE; STREPTOZOCIN; SUPPORT VECTOR MACHINES; TIME FACTORS;

EID: 84880042135     PISSN: 01692607     EISSN: 18727565     Source Type: Journal    
DOI: 10.1016/j.cmpb.2013.04.018     Document Type: Article

References (36)

1. Christoph T., De Vry J., Schiene K., Tallarida R.J., Tzschentke T.M. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. European Journal of Pharmacology 2011, 666:72-79.
2. Davis M.P. What is new in neuropathic pain?. Supportive Care in Cancer 2007, 15(4):363-372.
3. Davis M.P. Recent advances in the treatment of pain. F1000 Medical Report 2010, 2:63.
4. Gilron I., Bailey J.M., Tu D., Holden R.R., Jackson A.C., Houlden R.L. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009, 374(9697):1252-1261.
5. Miranda H.F., Noriega V., Prieto J.C. Previous administration of naltrexone did not change synergism between paracetamol and tramadol in mice. Pharmacology Biochemistry and Behavior 2012, 102(1):72-76.
6. Takeuchi Y., Takasu K., Ono H., Tanabe M. Pregabalin S-(+)-3-isobutylgaba activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology 2007, 53(7):842-853.
7. Yamama Y., Nishikawa K., Funao T., Mori T., Asada A. Intrathecal gabapentin and clonidine synergistically inhibit allodynia in spinal nerve-ligated rats. Life Sciences 2010, 87(17/18):565-571.
8. Beyreuther B.K., Callizot N., Brot M.D., Feldman R., Bain S.C., Stöhr T. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. European Journal of Pharmacology 2007, 565(1-3):98-104.
9. Mc Cleane G. Lacosamide for pain. Expert Opinion on Investigational Drugs 2010, 19(9):1129-1134.
10. Cheng J.K., Chiou L.C. Mechanisms of the antinociceptive action of gabapentin. Journal of Pharmacological Sciences 2006, 100(5):471-486.
11. Rahman W., Bauer C.S., Bannister K., Vonsy J.L., Dolphin A.C., Dickenson A.H. Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. Molecular Pain 2009, 5:45.
12. Luszczki J.J., Kolacz A., Czuczwar M., Przesmycki K., Czuczwar S.J. Synergistic interaction of gabapentin with tiagabine in the formalin test in mice: an isobolographic analysis. European Journal of Pain 2009, 13(7):665-672.
13. Abdel-Salam O.M., Sleem A.A. Study of the analgesic, anti-inflammatory, and gastric effects of gabapentin. Drug Discoveries and Therapeutics 2009, 3(1):18-26.
14. Hurley R.W., Chatterjea D., Rose Feng M., Taylor C.P., Hammond D.L. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology 2002, 97(5):1263-1273.
15. Baidya D.K., Agarwal A., Khanna P., Arora M.K. Pregabalin in acute and chronic pain. Journal of Anaesthesiology Clinical Pharmacology 2011, 27(3):307-314.
16. Laughlin T.M., Tram K.V., Wilcox G.L., Birnbaum A.K. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. Journal of Pharmacology and Experimental Therapeutics 2002, 302(3):1168-1175.
17. 2+ channels. Molecular Pain 2010, 6:97.
18. Pexton T., Moeller-Bertram T., Schilling J.M., Wallace M.S. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert Opinion on Investigational Drugs 2011, 20(9):1277-1284.
19. Perret D., Luo Z.D. Targeting voltage-gated calcium channels for neuropathic pain management. Neurotherapeutics 2009, 6(4):679-692.
20. Miranda H.F., Puig M.M., Prieto J.C., Pinardi G. Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain. Pain 2006, 121(1/2):22-28.
21. Schug S.A. Combination analgesia in 2005 - a rational approach: focus on paracetamol-tramadol. Clinical Rheumatology 2006, 25(Suppl. 1):16-21.
22. Sałat K., Filipek B., Wieckowski K., Malawska B. Analgesic activity of 3-mono-substituted derivatives of dihydrofuran-2-one in experimental rodent models of pain. Pharmacological Reports 2009, 61(5):807-818.
23. Salat K., Moniczewski A., Salat R., Janaszek M., Filipek B., Malawska B., Wieckowski K., Analgesic anticonvulsant and antioxidant activities of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one dihydrochloride in mice. Pharmacology Biochemistry and Behavior 2012, 101(1):138-147.
24. Salat R., Salat K. New approach to predicting proconvulsant activity with the use of Support Vector Regression. Computers in Biology and Medicine 2012, 42(5):575-581.
25. Vapnik V. Statistical Learning Theory 1998, Wiley, New York, NY.
26. Smola A., Scholkopf B. A Tutorial on Support Vector Regression, Neurocolt Technical Report NV2-TR-1998-030, London, UK 1998.
27. Salat R., Osowski S. Accurate fault location in the power transmission line using Support Vector Machine approach. IEEE Transactions on Power Systems 2004, 2:979-986.
28. Salat R., Osowski S. Support Vector Machine for soft fault location in electrical circuits. Journal of Intelligent and Fuzzy Systems 2011, 22(1):21-31.
29. Kim D., Lee H., Cho S. Response modeling with support vector regression. Expert Systems with Applications 2008, 34:1102-1108.
30. Tanabe M., Murakami T., Ono H. Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozocin-induced diabetic neuropathy. Journal of Pharmacological Sciences 2008, 107:213-220.
31. Drucker H., Burges C., Kaufman L., Smola A., Vapnik V. Support Vector Regression machines. Advances in Neural Information Processing Systems 1997, 9:155-161.
32. Chang C., Lin C. LIBSVM: a library for support vector machines. ACM Transactions on Intelligent Systems and Technology 2011, 2(3):1-27.
33. Jickling G., Heino A., Ahmed S.N. Acetaminophen toxicity with concomitant use of carbamazepine. Epileptic Disorders 2009, 11(4):329-332.
34. Pergolizzi J.V., Labhsetwar S.A., Puenpatom R.A., Joo S., Ben-Joseph R., Summers K.H. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Practice 2011, 11(4):325-336. 10.1111/j.1533-2500.2010.00438.x.
35. Pergolizzi J.V., Labhsetwar S.A., Puenpatom R.A., Joo S., Ben-Joseph R.H., Summers K.H. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Practice 2011, 11(3):230-239. 10.1111/j.1533-2500.2010.00413.x.
36. Toth C. Drug safety evaluation of pregabalin. Expert Opinion on Drug Safety 2012, 11(3):487-502. 10.1517/14740338.2012.677026.